Drugs / FP008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06990698 | Jun 2025 → May 2028 expected | cancer | Zhuhai Fapon Biopharma Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | Fapon Biotherapy Inc. | Results 破解PD-1耐药困局！菲鹏制药新型抗体融合蛋白登上国际顶刊 fapon.com ↗
在CT26和MC38结肠癌模型中，这种融合蛋白以剂量依赖性方式显著抑制肿瘤生长，效果显著优于单独使用抗PD-1抗体或IL-10-Fc，证明了其联合作用的优势。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | Fapon Biotherapy Inc. | 破解PD-1耐药困局！菲鹏制药新型抗体融合蛋白登上国际顶刊 fapon.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990698 ↗ |
| Route | Intravenous | “FP008 should be administered intravenous weekly.” NCT06990698 ↗ |